About

Dr. Rubinstein is an assistant professor and malignant hematologist at the University of North Carolina Chapel Hill and an associate member of the Lineberger Comprehensive Cancer Center. His primary clinical and research area of interest is plasma cell dyscrasias, and he is focused on clinical trials designed to improve the standard of care of patients with these disorders. In addition to clinical trials, Dr. Rubinstein has an informatics background, which he has leveraged to develop multiple prognostic scoring tools that are useful in the management of patients with plasma cell dyscrasias.

During the COVID-19 pandemic, Dr. Rubinstein also developed an interest in the impacts of COVID-19 on patients with cancer. He serves as the site PI of the COVID-19 and cancer consortium (CCC19) at ºÚÁÏÍø, and in this capacity has contributed to a number of studies derived from CCC-19 data to answer clinically relevant questions about the epidemiology and outcomes of patients with cancer and COVID-19.